175 related articles for article (PubMed ID: 38110620)
1. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
McCarthy PL; Attwood KM; Liu X; Chen GL; Minderman H; Alousi A; Bashey A; Lowsky R; Miklos DB; Hansen J; Westervelt P; Yanik G; Waller EK; Howard A; Blazar BR; Wallace PK; Reshef R; Horowitz MM; Maziarz RT; Levine JE; Mohammadpour H
Bone Marrow Transplant; 2024 Mar; 59(3):334-343. PubMed ID: 38110620
[TBL] [Abstract][Full Text] [Related]
2. Increased Galectin-9 expression, a prognostic biomarker of aGVHD, regulates the immune response through the Galectin-9 induced MDSC pathway after allogeneic hematopoietic stem cell transplantation.
Yin J; Li L; Wang C; Zhang Y
Int Immunopharmacol; 2020 Nov; 88():106929. PubMed ID: 32889240
[TBL] [Abstract][Full Text] [Related]
3. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation.
Pedraza A; Salas MQ; Rodríguez-Lobato LG; Escribano-Serrat S; Suárez-Lledo M; Martínez-Cebrian N; Solano MT; Arcarons J; Rosiñol L; Gutiérrez-García G; Fernández-Avilés F; Moreno-Castaño AB; Molina P; Pino M; Carreras E; Díaz-Ricart M; Rovira M; Palomo M; Martínez C
Transplant Cell Ther; 2024 Feb; 30(2):187.e1-187.e12. PubMed ID: 38000709
[TBL] [Abstract][Full Text] [Related]
4. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
6. Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.
Rashidi A; Shanley R; Holtan SG; MacMillan ML; Blazar BR; Khoruts A; Weisdorf DJ
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2190-2196. PubMed ID: 30454871
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
8. Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.
Holtan SG; Newell LF; Cutler C; Verneris MR; DeFor TE; Wu J; Howard A; MacMillan ML; Antin JH; Blazar BR; Weisdorf DJ; Panoskaltsis-Mortari A
Bone Marrow Transplant; 2017 Sep; 52(9):1300-1303. PubMed ID: 28581470
[TBL] [Abstract][Full Text] [Related]
9. Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.
Rashidi A; Shanley R; Yohe SL; Thyagarajan B; Curtsinger J; Anasetti C; Waller EK; Scott BL; Blazar BR; Weisdorf DJ
Br J Haematol; 2018 Sep; 182(6):887-894. PubMed ID: 30004111
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide.
Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J
Front Immunol; 2019; 10():2319. PubMed ID: 31632401
[No Abstract] [Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.
Bäuerlein CA; Qureischi M; Mokhtari Z; Tabares P; Brede C; Jordán Garrote AL; Riedel SS; Chopra M; Reu S; Mottok A; Arellano-Viera E; Graf C; Kurzwart M; Schmiedgen K; Einsele H; Wölfl M; Schlegel PG; Beilhack A
Front Immunol; 2020; 11():593321. PubMed ID: 33584657
[TBL] [Abstract][Full Text] [Related]
13. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
Ponce DM; Hilden P; Mumaw C; Devlin SM; Lubin M; Giralt S; Goldberg JD; Hanash A; Hsu K; Jenq R; Perales MA; Sauter C; van den Brink MR; Young JW; Brentjens R; Kernan NA; Prockop SE; O'Reilly RJ; Scaradavou A; Paczesny S; Barker JN
Blood; 2015 Jan; 125(1):199-205. PubMed ID: 25377785
[TBL] [Abstract][Full Text] [Related]
14. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
Rashidi A; DiPersio JF; Westervelt P; Abboud CN; Schroeder MA; Cashen AF; Pusic I; Romee R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1137-1141. PubMed ID: 26988741
[TBL] [Abstract][Full Text] [Related]
15. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
16. Platelet and Red Blood Cell Transfusions and Risk of Acute Graft-versus-Host Disease after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Sørensen ALT; von Stemann JH; Fischer-Nielsen A; Hansen MB; Sengeløv H; Ostrowski SR
Transplant Cell Ther; 2021 Oct; 27(10):866.e1-866.e9. PubMed ID: 34252580
[TBL] [Abstract][Full Text] [Related]
17. Multiple functional variants in the
Karaesmen E; Hahn T; Dile AJ; Rizvi AA; Wang J; Wang T; Haagenson MD; Preus L; Zhu Q; Liu Q; Yan L; Liu S; Haiman CA; Stram D; Pooler L; Sheng X; Van Den Berg D; Brock G; Webb A; McCarthy PL; Pasquini MC; Spellman SR; Lee SJ; Paczesny S; Sucheston-Campbell LE
Blood Adv; 2019 Aug; 3(16):2512-2524. PubMed ID: 31455667
[TBL] [Abstract][Full Text] [Related]
18. [Prediction of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation by the level of galectin-9 in peripheral blood].
Yin J; Cao Y; Zhou JF; Zhang YC
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):23-27. PubMed ID: 32023750
[No Abstract] [Full Text] [Related]
19. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
[TBL] [Abstract][Full Text] [Related]
20. The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant.
Stratton J; Sylvia A; Hoodin F; Choi SW; Pawarode A; Giordani B; Votruba K
Clin Neuropsychol; 2020 Jul; 34(5):969-980. PubMed ID: 31619131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
